Background and Objectives: This study investigated if pretreatment ethyl glucuronide (EtG) levels corresponding to light (100 ng/ mL), heavy (500 ng/mL), and very heavy (1,000 ng/mL) drinking predicted longest duration of alcohol abstinence (LDA) and proportion of EtG-negative urine tests in outpatients receiving a 12-week EtG-based contingency management (CM) intervention for alcohol dependence. Methods: Participants were 40 adults diagnosed with alcohol use disorders and serious mental illness who submitted up to 12 urine samples for EtG analysis during a 4-week observation period and were then randomized to 12-weeks of CM for alcohol abstinence and addiction treatment attendance. Alcohol use outcomes during CM as assessed by EtG and self-report were compared across those who did and did not attain a pre-treatment average EtG level of 500 ng/mL-a level that equates to frequent heavy drinking. Results: Only the 500 ng/mL cutoff was associated with significant differences in LDA and proportion of EtG-negative samples during CM. Those with a pre-treatment EtG < 500 ng/mL attained a LDA 2.3 (alcohol) to 2.9 (drugs) weeks longer than pre-treatment heavy drinkers. Discussion and Conclusions: The EtG biomarker can be used to determine who will respond to a CM intervention for alcohol use disorders and could inform future trials that are designed to be tailored to individual patients. Scientific Significance: Results suggest pre-treatment EtG cutoffs equivalent to heavy and very heavy drinking predict outcomes in CM. (Am J Addict 2017;26:673-675) 
INTRODUCTION
Contingency management (CM) is an intervention in which reinforcers, such as vouchers or prizes, are provided when individuals demonstrate illicit drug abstinence, typically measured multiple times per week. 1 While numerous studies have documented the efficacy of CM for illicit drugs and cigarette smoking, research investigating CM as a treatment for alcohol use disorders has been limited due to lack of a suitable alcohol biomarker to verify use for 2 or more days. 2, 3 However, ethyl glucuronide (EtG), a hepatic metabolite of alcohol detectable in urine, addresses this need.
In a recent study, the EtG alcohol biomarker was used to verify abstinence in a randomized controlled trial of CM for alcohol use disorders using a relatively low-cost EtG immunoassay. 4 In this trial, 79 adults diagnosed with alcohol dependence and serious mental illness participated in 4-week pre-randomization observation period during which they submitted urine samples for EtG testing three times each week. They were randomized to receive 12-weeks of CM for EtG-negative urine samples (EtG < 150 ng/mL) and addiction treatment attendance, or non-contingent reinforcement in which they received reinforcement for submitting urine samples regardless of EtG results. Relative to controls, CM participants were three times more likely to submit an alcohol-negative urine sample during treatment and attained an average of 1.5 weeks of additional abstinence, as assessed by EtG.
While overall response to CM was positive, in previous studies pre-treatment drug-positive urine tests are associated with lower levels of abstinence during CM. [5] [6] [7] These studies used point-of-care urine drug tests, which provide limited information (positive/negative) with which to predict CM treatment response. In contrast, the present study used an EtG immunoassay, which provides continuous results from 0 to 2,000 ng/mL. In our previous work, we have found that EtG cutoffs of 100, 500, and 1,000 ng/mL correspond to recent light, heavy, and very heavy drinking, respectively. 8 Therefore, the EtG immunoassay allows us to determine which of these clinically relevant EtG cutoffs best predicts treatment outcomes.
In this secondary analysis, we investigated whether an EtG cutoff that was comparable to light, heavy or very heavy drinking best discriminated between those who did and did not respond to the CM intervention, as assessed by longest duration of abstinence (LDA) from alcohol and the odds of submitting an alcohol-negative EtG test during CM. Results could allow clinicians to use EtG tests, including new point-of-care tests, to identify individuals who are likely or unlikely to respond to CM.
METHOD Participants
Participants were adults enrolled in state-certified outpatient addiction treatment at a multisite community mental health and addiction treatment agency, who met DSM-IV-TR criteria for alcohol dependence, and schizophrenia, schizoaffective disorder, bipolar I or II, or recurrent major depressive disorder as assessed by the MINI International Neuropsychiatric Interview. Seventy-nine individuals were randomized. This secondary data analysis included only those allocated to CM (n ¼ 40). Participants provided written informed consent and procedures were approved by the University of Washington's Human Subjects Division.
Study Design
Participants received treatment-as-usual including case management, medication management and housing, and vocational services throughout the study. Upon enrollment they participated in a 4-week pre-treatment observation period in which they received reinforcers contingent on providing urine samples three times per week regardless of EtG-results. Participants who attended at least one visit during week 4 and provided at least one EtG-positive urine sample were randomized.
Participants randomized to CM (n ¼ 40) submitted urine samples for EtG testing three times per week for 12 weeks. They engaged in the variable magnitude of reinforcement procedure each time they tested negative for EtG (<150 ng/mL). This involved making "prize draws" from a bucket containing tokens representing different magnitudes of reinforcement.
1 Prizes included toiletries, clothing, grocery and retail gift cards, small kitchen appliances, and electronics, (average total value earned by participants ¼ $175.03, SD ¼ $183.17). In addition, every week, participants received gift cards for attending all ($10) or at least one ($5) of their scheduled addiction treatment group sessions.
Measures
Participants provided urine samples three times per week during pretreatment and CM. Urine samples were analyzed onsite using the Diagnostic Reagents Incorporated EtG-immunoassay with a Thermo Fisher Indiko analyzer (Fremont, CA). Samples were considered alcohol-negative if EtG < 150 ng/mL. Tests were conducted using EtG 100, 500, 1000, 2000 ng/mL, and Negative calibrators and 100 and 375 ng/mL controls. The cutoff was set at 150, 50 ng/mL above the lower limit of detection for the EtG biomarker to allow for regular fluctuation in the Indiko instrumentation. Calibrations occurred weekly. Participants were asked to avoid nonbeverage sources of ethanol (ie, mouthwash and cough syrup).
Data Analysis
The average pre-treatment EtG score of each participant was calculated based on 12 pre-treatment urine samples collected over 4-weeks. These mean scores were then recoded into three different variables based on the following cutoff levels: <100 ng/mL (yes/no), <500 ng/mL (yes/no), and <1,000 ng/ mL (yes/no). Longest duration of alcohol abstinence (highest number of consecutive EtG-negative urine tests; missing tests were considered EtG-positive and ended the period of abstinence) was compared across each of the three cutoff level variables using independent samples t-tests. We utilized generalized estimating equations (GEE) to investigate whether pretreatment period average EtG level predicted proportion of EtG-negative urine samples submitted during the CM phase. The main effect of each cutoff level variable was investigated in three separate analyses. For GEE analyses we present odds ratios, and 95% confidence intervals. The criterion for statistical significance was set at alpha p < .05. Analyses were conducted using IBM SPSS version 23. Figure 1 demonstrates, those who attained an average pretreatment EtG level <100 ng/mL did not differ in LDA (n ¼ 11, In GEE analyses, participants who attained a pretreatment EtG level <100 ng/mL were 6.67 times more likely (95% CI ¼ 2.07-21.46) to submit EtG-negative urine samples in the treatment period, relative to those with EtG > 99 ng/mL. When the 500 ng/mL cutoff was examined, participants with pretreatment EtG < 500 ng/mL were 10.16 times more likely (95% CI ¼ 3.58-28.84) to submit EtG-negative urine samples, relative to those who had an average EtG > 499 ng/mL. Finally, those who attained a pretreatment EtG level <1000 ng/mL were 12.33 times more likely (95% CI ¼ 2.78-54.67) to submit EtG-negative samples, compared to those with a pretreatment EtG > 999 ng/mL.
RESULTS

As
DISCUSSION
Because pre-treatment drug-positive urine tests are a strong predictor of treatment outcome, particularly in CM, [5] [6] [7] we used EtG to identify a specific cutoff associated with CM treatment response. The 500 ng/mL cutoff was the only cutoff associated with both LDA and proportion of EtG-negative samples submitted during CM. Participants who had a pretreatment mean EtG > 499 ng/mL attained 2.3 fewer weeks of alcohol abstinence than those with an EtG < 500 ng/mL, indicating that the CM intervention was ineffective for this subsample. The LDA for this group was equal to that of participants in the control condition.
The 100 and 1,000 ng/mL cutoffs were also associated with the proportion of EtG samples submitted during CM. The strength of the association between mean pretreatment EtG levels and EtGnegative results during treatment increased as the pretreatment EtG cutoff increased (ie, OR ¼ 6.61 at 100 ng/mL, OR ¼ 10.16 at 500 ng/mL, OR ¼ 12.13 at 1,000 ng/mL). Therefore, individuals with higher pretreatment EtG levels were less likely to submit EtG samples consistent with abstinence during CM.
Limitations include the relatively small sample size, restricting our ability to conduct more sophisticated analyses in which we could account for other variables that might predict CM outcomes. However, the effect of pre-treatment EtG levels on CM outcomes was large, and likely to remain even after accounting for confounds. Other limitations include recruitment from one site, the possibility that results may not generalize to adults without SMI, feasibility issues of the benchtop analyzer needed to conduct EtG tests, and the limited practicality of conducting multiple EtG tests prior to treatment (sensitivity analysis found the results of a single baseline EtG test were not associated with alcohol outcomes). Newly available point-of-care EtG immunoassays with a cutoff of 500 ng/mL would allow clinicians to more feasibly identify CM responders versus non-responders and implement CM.
EtG can be used to identify those who are likely to respond to an abstinence-based CM intervention for alcohol use disorders, with 500 ng/mL predicting LDA and proportion of EtG-negative samples during CM. EtG has potential to personalize treatment for adults with alcohol use disorders. For those unlikely to respond to a typical CM intervention, modifications such as increasing the magnitude of reinforcement or requiring reductions in drinking before abstinence might improve outcomes. Alternatively, other interventions such as medication management may be needed to improve outcomes for CM non-responders. Future research should investigate whether pre-treatment EtG levels predict outcomes in other psychosocial and pharmacological interventions, and strategies for improving the efficacy of CM for heavy drinkers.
